Targeting the Human T-Cell Inducible COStimulator Molecule with a Monoclonal Antibody Prevents Graft-vs-Host Disease and Preserves Graft vs Leukemia in a Xenograft Murine Model by Aude Burlion, Simon Brunel, Nicolas Y. Petit, Daniel Olive, Gilles Marodon

“…In contrast, 65% of the mice receiving a single injection of the anti-hICOS mAb survived beyond 100 days. Moreover, a significant improvement in survival was obtained in a curative xeno-GVHD setting. …”
Get full text

Timing of hepatitis C treatment initiation and retention in office-based opioid treatment with buprenorphine: a retrospective cohort study by Mary L. Geist, Andrea C. Radick, Judith I. Tsui, Kendra L. Blalock, Addy Adwell, Elsabeth Tamru, Nancy C. Connolly, Jocelyn R. James

“…We also analyzed a subset of patients retained at least 100 days in OBOT care and evaluated whether HCV treatment during that period was associated with OBOT retention beyond 100 days. Results Of 191 HCV-infected OBOT patients, 30% initiated HCV treatment, of whom 31% received early treatment and 69% received late treatment. …”
Get full text

Cardiopoietic stem cell therapy in ischaemic heart failure: long‐term clinical outcomes by Jozef Bartunek, Andre Terzic, Beth A. Davison, Atta Behfar, Ricardo Sanz‐Ruiz, Wojciech Wojakowski, Warren Sherman, Guy R. Heyndrickx, Marco Metra, Gerasimos S. Filippatos, Scott A. Waldman, John R. Teerlink, Timothy D. Henry, Bernard J. Gersh, Roger Hajjar, Michal Tendera, Stefanie Senger, Gad Cotter, Thomas J. Povsic, William Wijns, for the CHART Program

“…Landmark analyses suggested late clinical benefit in patients with significant left ventricular enlargement receiving adequate dosing. Specifically, beyond 100 days of follow‐up, patients with left ventricular end‐diastolic volume of 200–370 mL treated with ≤19 injections of cardiopoietic stem cells showed reduced risk of death or cardiovascular hospitalization (hazard ratio 0.38, 95% CI 0.16–0.91, P = 0.031) and cardiovascular death or heart failure hospitalization (hazard ratio 0.28, 95% CI 0.09–0.94, P = 0.040). …”
Get full text

Isoprostanoid Plasma Levels Are Relevant to Cerebral Adrenoleukodystrophy Disease by Cinzia Signorini, Claudio De Felice, Thierry Durand, Jean-Marie Galano, Camille Oger, Silvia Leoncini, Joussef Hayek, Jetty Chung-Yung Lee, Troy C. Lund, Paul J. Orchard

“…Three ALD groups were classified according to patients with: (1) confirmed diagnosis of ALD but without cerebral disease; (2) cerebral disease in early period post-HSCT (<100 days post-HSCT) and on intravenous N-acetyl-L-cysteine (NAC) treatment; (3) cerebral disease in late period post-HSCT (beyond 100 days post-HSCT) and off NAC therapy. In our observation, when compared to healthy subjects (<i>n</i> = 29), in ALD (i), F₂-IsoPs levels were significantly (<i>p</i> < 0.01) increased in all patients, with the single exception of the early ALD and on NAC subjects; (ii) significant elevated (<i>p</i> < 0.0001) amounts of F₂-dihomo-IsoPs were detected, with the exception of patients with a lack of cerebral disease; (iii), a significant increase (<i>p</i> < 0.003) in F₄-NeuroP plasma levels was detected in all ALD patients. …”
Get full text